TYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarization.
[BACKGROUND AND AIM] M2-polarized tumor-associated macrophages (M2 TAMs) are known to promote cancer progression, and exosomes are crucial mediators of communication within the tumor microenvironment
APA
Zhong D, Liao Y, et al. (2024). TYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarization.. Journal of gastroenterology and hepatology, 39(12), 2926-2939. https://doi.org/10.1111/jgh.16783
MLA
Zhong D, et al.. "TYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarization.." Journal of gastroenterology and hepatology, vol. 39, no. 12, 2024, pp. 2926-2939.
PMID
39496400
Abstract
[BACKGROUND AND AIM] M2-polarized tumor-associated macrophages (M2 TAMs) are known to promote cancer progression, and exosomes are crucial mediators of communication within the tumor microenvironment (TME). However, the specific role of exosomes derived from M2 TAMs in pancreatic cancer (PC) progression remains poorly understood. Tyrosine kinase binding protein (TYROBP, also known as DAP12 for DNAX activating protein-12) is a transmembrane signal transduction polypeptide that interacts with immune cell receptors, influencing cellular functions via signal transduction pathways. TYROBP is prominently found in M2 TAMs exosomes, facilitating its transfer to PC cells and suggesting a potential role in PC pathogenesis.
[METHODS] This study initially confirmed the presence of TYROBP in M2 TAMs exosomes and its transfer to PC cells via exosomes. The impact of TYROBP on PC proliferation, apoptosis, migration, and invasion was investigated. Special attention was given to TYROBP's influence on PC metastasis and its underlying mechanisms, focusing particularly on the CD44/AKT/ERK signaling pathway.
[RESULTS] TYROBP expression in PC cells did not significantly affect tumor cell proliferation or apoptosis but demonstrated a notable inhibitory effect on migration and invasion, which was mediated through the CD44/AKT/ERK pathway. Both in vivo and in vitro experiments consistently showed that TYROBP enhanced PC metastasis.
[CONCLUSIONS] This study elucidates that TYROBP plays a direct role in promoting PC metastasis through its association with M2 TAMs polarization. Therefore, TYROBP represents a potential novel therapeutic target for interventions aimed at combatting PC progression.
[METHODS] This study initially confirmed the presence of TYROBP in M2 TAMs exosomes and its transfer to PC cells via exosomes. The impact of TYROBP on PC proliferation, apoptosis, migration, and invasion was investigated. Special attention was given to TYROBP's influence on PC metastasis and its underlying mechanisms, focusing particularly on the CD44/AKT/ERK signaling pathway.
[RESULTS] TYROBP expression in PC cells did not significantly affect tumor cell proliferation or apoptosis but demonstrated a notable inhibitory effect on migration and invasion, which was mediated through the CD44/AKT/ERK pathway. Both in vivo and in vitro experiments consistently showed that TYROBP enhanced PC metastasis.
[CONCLUSIONS] This study elucidates that TYROBP plays a direct role in promoting PC metastasis through its association with M2 TAMs polarization. Therefore, TYROBP represents a potential novel therapeutic target for interventions aimed at combatting PC progression.
MeSH Terms
Pancreatic Neoplasms; Humans; Exosomes; Adaptor Proteins, Signal Transducing; Animals; Tumor Microenvironment; Tumor-Associated Macrophages; Cell Proliferation; Signal Transduction; Apoptosis; Cell Movement; Neoplasm Invasiveness; Cell Line, Tumor; Disease Progression; Membrane Proteins
같은 제1저자의 인용 많은 논문 (5)
- Unveiling the Scientific Landscape and Trends of Cutaneous Immune-Related Adverse Events: A Bibliometric Analysis.
- Improving Lung Cancer Screening Selection: A Comparative Analysis of Risk Models and Traditional Criteria in a Western European General Population.
- KCTD1 stabilizes c-Myc to upregulate PD-L1 and suppress anti-tumor immunity in hepatocellular carcinoma.
- Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy.
- Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.